Integrated Biopharma Financials
Based on the key measurements obtained from Integrated Biopharma's financial statements, Integrated Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.
With this module, you can analyze Integrated financials for your investing period. You should be able to track the changes in Integrated Biopharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Integrated |
Understanding current and past Integrated Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Integrated Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Integrated Biopharma's assets may result in an increase in income on the income statement.
The data published in Integrated Biopharma's official financial statements typically reflect Integrated Biopharma's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Integrated Biopharma's quantitative information. For example, before you start analyzing numbers published by Integrated accountants, it's essential to understand Integrated Biopharma's liquidity, profitability, and earnings quality within the context of the Personal Products space in which it operates.
Integrated Biopharma Stock Summary
Integrated Biopharma competes with Premier Foods, Aryzta AG, Calbee, Toyo Suisan, and Treehouse Foods. Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.Specialization | Consumer Defensive, Packaged Foods |
Instrument | USA OTC Stock View All |
Exchange | OTCQX Exchange |
ISIN | US45811V1052 |
CUSIP | 45811V105 163527203 45818E106 |
Location | New Jersey; U.S.A |
Business Address | Building 15, Hillside, |
Sector | Personal Products |
Industry | Consumer Staples |
Benchmark | Dow Jones Industrial |
Website | www.ibiopharma.com |
Phone | 888 319 6962 |
Currency | USD - US Dollar |
Integrated Biopharma Key Financial Ratios
Integrated Biopharma's financial ratios allow both analysts and investors to convert raw data from Integrated Biopharma's financial statements into concise, actionable information that can be used to evaluate the performance of Integrated Biopharma over time and compare it to other companies across industries.Integrated Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Integrated Biopharma's current stock value. Our valuation model uses many indicators to compare Integrated Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integrated Biopharma competition to find correlations between indicators driving Integrated Biopharma's intrinsic value. More Info.Integrated Biopharma is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.26 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Integrated Biopharma is roughly 3.77 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Integrated Biopharma's earnings, one of the primary drivers of an investment's value.Integrated Biopharma Thematic Clasifications
Integrated Biopharma is part of several thematic ideas from Natural Foods to Processed Foods. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Transaction History View history of all your transactions and understand their impact on performance | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |